Temasek and GIC acquire stake in Singapore-headquartered biotech specialist CRO Novotech
Novotech, Singapore-headquartered full-service biotech specialist clinical research organization (CRO), announced that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund, Novotech said in a statement...
0 Comments 0 Shares 966 Views 0 Reviews
Sponsored
Sponsored